The STIB score: a simple clinical test to predict clopidogrel resistance.

[en] STIB HPR score allows identification of patients with a high probability of resistance to clopidogrel based on diabetes, Hb<13.9g/dl and BMI > 28kg/m². This bedside clinical test could be useful for the indentification of patients in whom another P2Y12 inhibitor should be recommended before and after PCI.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Legrand, Delphine

Barbato, Emanuele

Chenu, Patrick

Magne, Julien

Vrolix, Mathy

Wijns, William

LEGRAND, Victor ; Centre Hospitalier Universitaire de Liège - CHU > Cardiologie

Language :

English

Title :

The STIB score: a simple clinical test to predict clopidogrel resistance.

Publication date :

2015

Journal title :

Acta Cardiologica

ISSN :

0001-5385

eISSN :

1784-973X

Publisher :

Acta Medica Belgica, Bruxelles, Belgium

Volume :

Pages :

522-527

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 December 2015

Statistics

Number of views

232 (1 by ULiège)

Number of downloads

355 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Brar SS, Ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-54.
Nijjer SS, Davies JE, Francis DP. Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. Int J Cardiol 2012; 158: 181-5.
The Task Force for the Management of Acute Coronary Syndromes (ACS) in patients presenting without Persistent ST-Segment Elevation of the European Society of cardiology (ESC). ESC Clinical Practice Guidelines. Eur Heart J 2011; 32: 2999-3054.
Legrand V, Cuisset T, Chenu P, Vrolix M, Martinez C, Dens J, Gach O, Boland J, Claeys MJ, Magne J, Barbato E, Wijns W. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease. The Stent Thrombosis in Belgium (STIB) trial. Eurointervention 2014; 10: 204-11.
Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention. A time-dependent analysis of the Gauging Responsiveness with a Verify Now P2Y12 Assay: Impact on the Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124: 1132-7.
Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097-105.
Angiolillo DJ, Fernandez-Ortiz A, Bernado E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual response to clopidogrel. Clinical implication, management and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16.
Angiolillo DJ, Fernandez-Ortiz A, Bernado E, Barrera Ramirez C, Sabate M, Fernandez C, Hernandez-Antolin R, Escaned J, Alfonso F, Macaya C. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading dose be weight adjusted? J Invasive Cardiol 2004; 16: 169-74.
Reny JL, Berdague P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, de Moerloose P, Fontana P; Antiplatelet Drug Resistances and Ischemic Events (ADRIE) Study Group. Antiplatelet Drug Resistances and Ischemic Events (ADRIE) Study Group. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 2012; 125: 3201-10.
Trenk D, Stone GW, Gawaz M. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents. Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel) Study. JACC 2012; 59: 2159-64.
Collet S, Barthelemy O, Range G, Van Belle E, Cuisset T, Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrie D, Rousseau H, Aubry P, Monsequ J, Sabouret P, O’Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G for ARTIC Investigators. Dual-Antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARTIC-Interruption): a randomised trial. Lancet 2014; 14: 60612-7.
Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review. JAMA 2013; 310: 189-98.
Samardzic J, Krpan M, Skoric B, Pasalic M, Petricevic M, Milicic D. Serial clopidogrel dose adjustment after platelet function testing improve outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity. J Thromb Thrombolysis 2014; 38: 459-69.
Mayer K, Schulz S, Bernlochner I, Morath T, Braun S, Hausleiter J, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sibbing D. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patient with high on-clopidogrel platelet reactivity. Result of the ISAR-HPR registry. Thromb Haemost 2014; 112: 342-51.
Montalescot G, Range G, Silvain J, Bonnet JL, Boueri Z, Barthelemy O, Cayla G, Belle L, Van Belle E, Cuisset T, Elhadad S, Pouillot C, Henry P, Motreff P, Carrie D, Rousseau H, Aubry P, Monsegu J, Sabouret P, O’Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Collet JP; ARCTIC Investigators. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARTIC study. Circulation 2014; 129: 2136-43.